Steffie Vonk

Research output

Research output per year 2021 2022 2024

• 6 Article

Research output per year

Research output per year

Search results

• 2024

  Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor

  Vonk, S. E. M., Altenburg, J., Mathôt, R. A. A. & Amsterdam Mucociliary Clearance Disease (AMCD) research group, 2024, (E-pub ahead of print) In: Journal of cystic fibrosis.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
• 2023

  Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series

  Vonk, S. E. M., Lub, R., Weersink, E. J. M. & Amsterdam mucociliary clearance disease research group, 2023, (E-pub ahead of print) In: Clinical therapeutics.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  1 Citation (Scopus)
• 2022

  No drug-drug interaction between tezacaftor-ivacaftor and clofazimine: A case report.

  Amsterdam Mucociliary Clearance Disease (AMCD) research group, 21 Jan 2022, In: Journal of cystic fibrosis. 21, 1, p. e5-e7

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  2 Citations (Scopus)

• Real-life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients

  Amsterdam Mucociliary Clearance Disease (AMCD) research group, 1 Dec 2022, In: Pharmacology research & perspectives. 10, 6, p. e01015 e01015.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  8 Citations (Scopus)

• Tobramycin and vestibulotoxicity: Retrospective analysis of four cases

  Vonk, S. E. M., Weersink, E. J. M., Majoor, C. J. & Kemper, M. M., 22 Mar 2022, In: European Journal of Hospital Pharmacy. ejhpharm-2020-002588.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  2 Citations (Scopus)
• 2021

  Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability

  Amsterdam Mucociliary Clearance Disease (AMCD) research group, 1 Aug 2021, In: Therapeutic drug monitoring. 43, 4, p. 555-563 9 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  7 Citations (Scopus)